Cibus Global LLC (CBUS)vsMerck & Company Inc (MRK)
CBUS
Cibus Global LLC
$1.94
0.00%
HEALTHCARE · Cap: $144.13M
MRK
Merck & Company Inc
$130.40
-1.11%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1534384% more annual revenue ($65.77B vs $4.29M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CBUS
Avoid28
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$17.87
Current Price
$1.94
$15.93 discount
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 62.6% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CBUS
The strongest argument for CBUS centers on Revenue Growth. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CBUS
The primary concerns for CBUS are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.78 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CBUS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CBUS carries more volatility with a beta of 1.65 — expect wider price swings.
CBUS is growing revenue faster at 62.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 28/100). CBUS offers better value entry with a 88.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cibus Global LLC
HEALTHCARE · BIOTECHNOLOGY · USA
Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?